Avistone Pharmaceuticals procures over $200m

Avistone Pharmaceuticals, a clinical-stage biotechnology company focused on precision oncology therapeutics, has raised over $200 million in funding.

8 December 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles